Pharmacokinetics of gefitinib and erlotinib

The Lancet Oncology

Volumn 12, Issue 12, 2011, Pages 1093-

  Levêque, Dominique ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; GEFITINIB;

AREA UNDER THE CURVE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84855721554     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70306-0     Document Type: Letter

References (3)

1. Mitsudomi T Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?. Lancet Oncol 2011, 12:710-711.
2. Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
3. Scholler J, Levêque D Molecular pharmacokinetic determinants of anticancer kinase inhibitors in humans. Oncol Rev 2011, 5:77-92.